Get the Stockscreener App
57.00
0.41%
0.23
After Hours:
56.94
-0.06
-0.11%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $57.00, with a volume of 10.81M.
It is up +0.41% in the last 24 hours and down -1.54% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$56.77
Open:
$56.64
24h Volume:
10.81M
Relative Volume:
0.93
Market Cap:
$116.40B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
16.00
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
+1.50%
1M Performance:
-1.54%
6M Performance:
+22.19%
1Y Performance:
+24.43%
1-Day Range:
$56.14
$57.10
1-Week Range:
$55.41
$57.10
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
57.00 | 115.93B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,004.92 | 897.72B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
226.71 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
210.39 | 372.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
148.08 | 285.77B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
181.58 | 286.84B | 60.48B | 10.40B | 8.05B | 3.3297 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Another pharma giant eyes Houston for $1B plant with hundreds of jobs possible - KHOU
Bristol Myers Squibb eyes Houston for $1B pharmaceutical plant - The Business Journals
Bristol Myers Squibb partners with Hengrui Pharma to develop and test drugs early in China. - Pluang
Biopharma Collaboration: Bristol Myers Squibb Partners with Heng - GuruFocus
Bristol Myers Squibb and Hengrui Forge $15.2 Billion Strategic Alliance, Reshaping China-Out Licensing Landscape - Oncodaily
Rx Rundown: Bristol Myers Squibb, Isomorphic Labs, Partner Therapeutics and more - Medical Marketing and Media
AustralianSuper Pty Ltd Decreases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Strategic Advisers Fidelity Alternatives Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Sivia Capital Partners, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts - Benzinga
Tempus AI Stock (TEM) Opinions on Bristol Myers Squibb Partnership Expansion - Quiver Quantitative
Bristol-Myers Squibb Company stock (US0897961004): Dividend paid May 1 - AD HOC NEWS
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience - The Joplin Globe
AI aims to reshape Bristol Myers’ cancer and Alzheimer’s drug trials - Stock Titan
Bristol-Myers Squibb stock (US1101221083): China deal worth up to $15.2B - AD HOC NEWS
Bristol Myers Squibb Company $BMY Shares Sold by Bank Julius Baer & Co. Ltd Zurich - MarketBeat
MCDONALD PARTNERS LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration - Genetic Engineering and Biotechnology News
Bristol-Myers Shuts Down Lawsuit Over Celgene Investor Rights - Bloomberg Law News
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Cortisone Shots Market 2026 | Merck & Co, Pfizer, Bristol-Myers Squibb, Novartis, Pharmascience etc. - openPR.com
Bristol-Myers Squibb stock (US0897961004): $15.2B Hengrui Pharma drug partnership - AD HOC NEWS
Bernstein reiterates Bristol-Myers Squibb stock rating on China deal By Investing.com - Investing.com India
BMY Partners with Hengrui for $15.2 Billion Early-Stage Drug Dev - GuruFocus
Bernstein reiterates Bristol-Myers Squibb stock rating on China deal - Investing.com
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Jiangsu Hengrui Pharmaceutical Signs $15.2 Billion Drug Deal With Bristol Myers Squibb Ahead of Trump’s China Visit - Daily Pioneer
M Stanley: HENGRUI PHARMA (01276.HK) Forms USD15.2B Strategic Partnership with Bristol-Myers Squibb Company (BMY.US) to Accelerate Globalization - AASTOCKS.com
Bristol Myers Squibb and Hengrui Pharma sign major licencing deal - FinanceAsia
NJ Court Not Sure Bristol-Myers Investor Pled Negligence - Law360
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Hengrui Pharma And Bristol Myers Squibb Forge $15.2 Billion Strategic Alliance Across Oncology And Immunology - BioPharma APAC
Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-Up - WSJ
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal - BioWorld News
BMS and Hengrui forge $15.2bn alliance for early-stage drugs - Pharmaceutical Technology
Bristol Myers Squibb (BMY) Valuation Check After Recent Share Weakness And Mixed 2024 Earnings - simplywall.st
Bristol Myers Squibb inks $15.2B drug deal with Hengrui - NJBIZ
Bristol Myers, Hengrui Pharma Team Up in Global Drug Research Pact That Could Top $15B - MedCity News
Bristol-Myers Squibb stock (US1101221083): Stock dips despite strong Q1 2026 earnings - AD HOC NEWS
BMO reiterates Bristol-Myers Squibb stock rating on Hengrui deal By Investing.com - Investing.com Nigeria
BMO reiterates Bristol-Myers Squibb stock rating on Hengrui deal - Investing.com UK
BMS and Hengrui Partner on 13 Oncology, Hematology, and Immunology Programs in Deal Worth Potentially $15.2 Billion - BioPharm International
Hengrui Pharma strikes $15.2 billion asset deal with BMS - The Pharma Letter
Hengrui Pharma and Bristol Myers Squibb Enter Strategic Collaboration to Advance Innovative Medicines - marketscreener.com
China's Hengrui, Bristol Myers Squibb sign collaboration, licensing deals - Reuters
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion - BioPharma Dive
BMS-Hengrui Pact Highlights China’s Rising Role in Drug Development - PharmTech.com
Hengrui Pharma and Bristol Myers Squibb to advance innovative medicines across oncology, hematology, immunology - BioSpectrum Asia
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal - BioSpace
China’s Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS - Yicai Global
BMS, Hengrui strike $15.2B multi-asset pact - FirstWord Pharma
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):